Hosted by The Life Raft Group, join us on May 21 at 12 PM ET for a candid, informative conversation about stepping into a clinical trial. Rashmi Chugh, MD of University of Michigan Rogel Comprehensive Cancer Center will present how clinical trials work, who they’re for, and what you can really expect and Dirk Niggemeyer, GIST patient, will share his personal journey navigating two clinical trials.
Whether you’re newly diagnosed, exploring new treatment options, or simply want to better understand clinical trials, this session will help you make more informed decisions with confidence.
These webinars are for informational purposes only and should not replace professional medical advice. Always consult your healthcare provider before making any treatment or lifestyle changes.
About Our Presenters:
Dr. Rashmi Chugh
University of Michigan Rogel Comprehensive Cancer Center
Dr. Rashmi Chugh is a Professor of Internal Medicine in the Division of Hematology/Oncology at the University of Michigan Rogel Comprehensive Cancer Center, Associate Division Chief of Clinical Services of Hematology/Oncology, and Sarcoma Clinical Research Team Co-Leader. Her clinical practice is focused on the care of patients with bone and soft tissue sarcoma including gastrointestinal stromal tumors. Dr. Chugh’s research involves conducting early and late phase clinical trials of novel therapies alone or in combination with a goal to advance the care of sarcoma patients. She also is Medical Co-Director of the Michigan Adolescent and Young Adult (AYA) Oncology Program and has a particular interest in the care and research surrounding the unique challenges this population faces.
Dirk Niggemeyer
Patient Advocate
Dirk Niggemeyerwas diagnosed with GIST (KIT Exon 11) in July 2018 when he went from Engineering Manager and youth soccer coach to palliative care patient overnight. He continued working until late 2021. Dirk has participated in two medical studies: For 15 months, he was in the control group in the Phase 3 Sutent vs Qinlock study, and he has been participating in the IDRX-42 Phase 1b study for the last 22 months
